 | Up a level |
Journal Article
Fraser, Graeme A. M., Chanan-Khan, Asher, Demirkan, Fatih, Santucci Silva, Rodrigo, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlovsky, Miguel A., Goy, Andre, Mato, Anthony, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Schuier, Natasha, Balasubramanian, Sriram, Howes, Angela and Cramer, Paula (2020). Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk. Lymphoma, 61 (13). S. 3188 - 3198. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
Wendtner, Clemens M., Hallek, Michael, Fraser, Graeme A. M., Michallet, Anne-Sophie, Hillmen, Peter, Durig, Jan, Kalaycio, Matt, Gribben, John G., Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J., Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay and Chanan-Khan, Asher (2016). Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leuk. Lymphoma, 57 (6). S. 1291 - 1300. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403